CME Available: https://auau.auanet.org/node/35599

Course Director: David A. Ginsberg, MD
Faculty: Anne P. Cameron, MD, FRCSC, FPMRS; Sara M. Lenherr, MD, MS, FPRMS, Eric Rovner, MD; Eric Rovner, MD

ACKNOWLEDGEMENTS
This educational activity is supported by an independent educational grant from:
Urovant

LEARNING OBJECTIVES
At the conclusion of the activity, participants will be able to:
1. Define the similarities and differences between the various oral pharmacotherapies for OAB and discuss the potential future pharmacological pathways and therapies.
2. Describe the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
3. Discuss optimal use of third line therapies in order to maximize clinical benefit.
4. Counsel patients on the pros and cons and risks and benefits of each of the third line therapies for OAB.

Ver todos los episodios